Assertio Therapeutics, Inc., formerly known as Depomed, is a specialty pharmaceutical company focused on the development and commercialization of therapies for central nervous system (CNS) disorders, including neuropathic pain, migraine and breakthrough cancer pain. The company’s commercial portfolio includes three FDA-approved products—Qutenza (8% capsaicin) for postherpetic neuralgia, Butrans (buprenorphine) transdermal system for chronic pain and Onsolis (fentanyl buccal soluble film) for breakthrough cancer pain—which are marketed primarily in the United States under licensing agreements with global partners.
In addition to its marketed therapies, Assertio maintains a pipeline of preclinical and clinical-stage candidates targeting a range of pain and neurological conditions. The firm leverages strategic collaborations to expand its product offerings and enhance patient access. Research and development efforts are supported by a commercial infrastructure that provides sales, marketing and medical affairs support across various U.S. territories.
Founded in 1995 as Depomed, the company rebranded to Assertio Therapeutics in late 2020 following a corporate restructuring designed to sharpen its focus on CNS disorders. Headquartered in Chicago, Illinois, Assertio operates a streamlined corporate structure to optimize efficiency and maintain healthy cash flows while pursuing growth through acquisitions and out-licensing opportunities. Its commercial reach is currently concentrated in North America, with plans to explore additional partnerships for international distribution.
Assertio’s leadership team is led by President and Chief Executive Officer Donald P. Deieso, who has directed the company’s transformation and efforts to revitalize its portfolio. Under Deieso’s guidance, Assertio continues to prioritize disciplined resource allocation and strategic collaboration to drive product innovation and deliver value to patients, healthcare providers and shareholders.
AI Generated. May Contain Errors.
